Home About Us FAQ Policies Contact Site Map
 
 
QUICK SEARCH
   Advanced Search
 
 
 
   
 
Stay updated on your favorite report topics! We are adding hundreds of new reports daily. Receive email alerts when those reports affect you!

Stay on top of your industry.
  
 

The Worldwide Influenza Market
Product Type: Market Research Report Publication Date: May 31, 2006
 
Download a sample from "The Infoshop", another service of Global Information.

SUMMARY

REPORT HIGHLIGHTS

  • By 2010, the worldwide influenza market is likely to reach $7.1 billion, with average annual growth estimated at 19.8%.
  • The worldwide influenza market is estimated at $2.9 billion in 2005, up from $1.5 billion the previous year.
  • The market is estimated to reach $7.1 billion in 2010, an increase of more than $4.2 billion over the forecast period.
  • The worldwide therapeutics/vaccines market is likely to reach $6.9 billion in 2010, with average annual growth estimated at 20.8%.

TABLE OF CONTENTS

INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE AND FORMAT
  • METHODOLOGY
  • RELATED BCC STUDIES
  • ANALYST CREDENTIALS
  • BCC ONLINE SERVICES
  • DISCLAIMER

SUMMARY

  • THE INFLUENZA MARKET: MAJOR MARKETS
  • Summary Table:
    • GLOBAL FORECAST OF THE INFLUENZA MARKET BY PRODUCT SEGMENT, THROUGH 2010 ($ MILLION)
  • Summary Figure:
    • WORLDWIDE INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT, 2003-2010 ($ MILLIONS)

INDUSTRY OVERVIEW

  • INDUSTRY OVERVIEW
  • Table 1 VACCINE RECOMMENDATIONS
  • HISTORY OF THE MARKET
    • EPIDEMICS/PANDEMICS
      • Spanish Influenza 1918-1919
      • Hong Kong Influenza 1968
      • Russian Influenza 1977
      • Asian Influenza 1957
      • Swine Flu 1976
      • Avian Flu 1961, 1997, 2003-Present
      • Virus Mutations
      • Types of Influenza
        • Influenza Type A
          • Influenza A H5
          • Influenza A H7
          • Influenza A H9
        • Influenza Type B
        • Influenza Type C
        • Table 2 WORLDWIDE INFLUENZA ACTIVITY
        • Table 22 (CONTINUED)
  • VIRAL SURVEILLANCE
  • Table 3 VIRAL SURVEILLANCE, PERCENTAGE OF INFLUENZA VIRUS TYPE, 2004-2005 AND 2005-2006 FLU SEASONS (%)
  • CURRENT H5N1 VIRUS "DRIFT AND SHIFT"
  • DEVELOPMENT OF FLU VACCINES
  • Table 4 INFLUENZA RESEARCH TEAMS AND AREAS OF STUDY
  • WORLD DEMOGRAPHICS AND INCIDENCE/MORTALITY
  • Table 5 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP, 2003-2010 (MILLIONS)
  • Figure 1 ESTIMATED WORLD POPULATION BY SELECTED AGE GROUP, 2003-2010 (MILLIONS)
  • Table 6 ESTIMATED WORLD POPULATION INCLUDING SOME COUNTRIES, 2003-2010 (MILLIONS)
  • Figure 2 ESTIMATED WORLD POPULATION BY REGION, 2003-2010 (MILLIONS)
  • Table 7 WORLDWIDE VIRAL STATISTICS, 2005
  • Table 8 UNITED STATES VIRAL STATISTICS, 2005

ISSUES AFFECTING THE MARKET

  • GOVERNMENT INTERVENTION
    • UNITED STATES
    • Table 9 COUNTRIES WITH U.S. EMBARGOES FOR BIRDS
    • Table 9 (CONTINUED)
      • Chinese and United States Governments
      • Turkey and the United States
    • WHO and CDC
      • WHO
      • Table 10 WHO REPORTED CASES OF AVIAN FLU IN HUMANS, MARCH 2006
      • The WHO and Containment Issues
      • Table 11 APPROVED WHO INFLUENZA CENTERS BY REGION
      • Table 11 (CONTINUED)
      • Table 11 (CONTINUED)
      • Table 11 (CONTINUED)
      • Table 11 (CONTINUED)
      • Table 11 (CONTINUED)
      • Table 11 (CONTINUED)
      • CDC
      • Table 12 CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE, 2003 TO PRESENT
      • Table 12 (CONTINUED)
    • LEGISLATION
      • Department of Defense, Emergency Supplemental Appropriations to Address Hurricanes in The Gulf of Mexico, and Pandemic Influenza Act, 2006
      • Global Network for Avian Influenza Surveillance Act
      • Pandemic Preparedness and Response Act
      • Pandemic and Seasonal Influenza Act Of 2005
      • Seasonal Influenza and Pandemic Preparation Act of 2005
      • National Biodefense and Pandemic Preparedness Act of 2005
    • EPIDEMIC/PANDEMIC PREPAREDNESS
    • Table 13 ALLOCATED FUNDS FOR INFLUENZA RESEARCH AND DEVELOPMENT
    • IMMATERIALIZED MARKET RISK
    • VACCINE STOCKPILES
    • MEDIA COVERAGE AND VACCINATIONS
    • EPIDEMIC/PANDEMIC THREAT
    • Table 14 ESTIMATED INCIDENCE OF INFLUENZA IN SEVERE OUTBREAKS BASED ON POPULATION ESTIMATES, U.S. CENSUS BUREAU INTERNATIONAL DATABASE
    • Table 14 (CONTINUED)
    • Table 14 (CONTINUED)
    • Table 15 PREDICTED IMPACT ON HEALTH SERVICES FROM THE NEXT INFLUENZA PANDEMIC IN THE TROPICS, BASED ON CDC'S FLUAID PREDICTION MODEL FOR PEAK WEEK

TECHNOLOGY

  • CURRENT USES OF TECHNOLOGY
    • CDC TESTING KIT
    • BD MEDICAL AND GLAXOSMITHKLINE
    • PATENT ANALYSIS
    • Table16 U.S. PATENT EVALUATION FOR MAJOR TECHNOLOGY BY ISSUE DATE
    • Table 16 (CONTINUED)
    • Table 16 (CONTINUED)
    • Table 16 (CONTINUED)
    • Table 16 (CONTINUED)
    • Table 16 (CONTINUED)
    • Table 16 (CONTINUED)
    • Table 16 (CONTINUED)
    • Table 16 (CONTINUED)
    • Table 16 (CONTINUED)
    • Table 16 (CONTINUED)
    • Table 16 (CONTINUED)
    • Table 16 (CONTINUED)
    • Table 16 (CONTINUED)
    • Table 17 U.S. PATENT EVALUATION FOR MAJOR INFLUENZA MARKET COMPETITORS, BY PATENT HOLDER AND NUMBER OF PATENTS
    • Figure 3 U.S. PATENT EVALUATION FOR MAJOR INFLUENZA TECHNOLOGY PATENT HOLDERS, BY PERCENT (%)
    • EMERGING AREAS OF TECHNOLOGY
      • Stmicroelectronics and Veredus Laboratories
      • Sanofi Pasteur and BD Biosciences
    • NASAL POWDER VACCINE

INFLUENZA THERAPIES/VACCINES

  • OVERVIEW
  • PRODUCT DESCRIPTIONS
    • PRODUCT DESCRIPTIONS (CONTINUED)
    • Table 18 MARKETED FLU VIRUS PRODUCTS, THROUGH 2005
    • Table 19 GENERIC AVAILABILITY
    • Table 20 VACCINE AVERAGE PRICE PER UNIT DOSE, 2005-2006 INFLUENZA SEASON
    • PRODUCT DESCRIPTIONS (CONTINUED)
    • PRODUCT DESCRIPTIONS (CONTINUED)
    • PRODUCT DESCRIPTIONS (CONTINUED)
    • PRODUCT DESCRIPTIONS (CONTINUED)
  • RESEARCH AND DEVELOPMENT
  • Table 21 RESEARCH AND DEVELOPMENT EFFORTS BY STATUS
  • Table 21 (CONTINUED)
  • Table 21 (CONTINUED)
  • MARKET ANALYSIS
  • Table 22 GLOBAL FORECAST FOR INFLUENZA THERAPEUTIC AND VACCINE REVENUES BY MARKET, THROUGH 2010 ($ MILLIONS)
  • Figure 4 GLOBAL FORECAST FOR INFLUENZA THERAPEUTICS AND VACCINES BY REGION, 2003-2010 ($ MILLIONS)
  • Table 23 GLOBAL FORECAST FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, THROUGH 2010 ($ MILLIONS)
  • Figure 5 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, 2003-2010 ($ MILLIONS)
  • Table 24 UNITS FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT, 2005-2006 SEASON (MILLION UNITS)
  • Figure 6 SHARE OF UNITS FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT, 2005-2006 SEASON (%)
  • LEADING SUPPLIERS AND PARTICIPANTS
  • Table 25 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, 2005 (%)
  • Figure 7 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, 2005 (%)

INFLUENZA DIAGNOSTICS

  • OVERVIEW
  • Table 26 INFLUENZA DIAGNOSTIC TABLE
  • Table 26 (CONTINUED)
  • PRODUCT DESCRIPTIONS
    • CONVENTIONAL LABORATORY TESTS
    • RAPID TESTING
    • Table 27 MARKETED PRODUCTS, THROUGH 2005
    • Table 27 (CONTINUED)
    • Table 28 RAPID INFLUENZA TESTS AVERAGE PRICE
    • LABORATORY TEST SERVICES
    • Table 29 PROVIDERS OF LABORATORY TEST SERVICES
  • MARKET ANALYSIS
  • Table 30 REVENUES FOR INFLUENZA DIAGNOSTICS BY MARKET, THROUGH 2010 ($ MILLIONS)
  • Figure 8 REVENUES FOR INFLUENZA DIAGNOSTICS BY MARKET, 2003-2010 ($ MILLIONS)
  • Table 31 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, THROUGH 2010 ($ MILLIONS)
  • Figure 9 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, 2003-2010 ($ MILLIONS)
  • Table 32 GLOBAL FORECAST OF INFLUENZA DIAGNOSTICS SERVICE REVENUES, THROUGH 2010 ($ MILLIONS)
  • Figure 10 REVENUES FOR INFLUENZA DIAGNOSTICS SERVICES, 2003-2010 ($ MILLIONS)
  • Table 33 GLOBAL FORECAST OF INFLUENZA DIAGNOSTIC PRODUCT AND SERVICES MARKET REVENUES, THROUGH 2010 ($ MILLION)
  • Figure 11 GLOBAL INFLUENZA DIAGNOSTIC PRODUCT AND SERVICES MARKET REVENUES, 2003-2010 ($ MILLION)
  • LEADING SUPPLIERS AND PARTICIPANTS
  • Table 34 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENT, 2005 (%)
  • Figure 12 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENT, 2005 (%)

MARKET SUMMARY

  • TOTAL MARKET ANALYSIS
  • Table 35 GLOBAL FORECAST OF THE INFLUENZA MARKET BY PRODUCT SEGMENT, THROUGH 2010 ($ MILLION)
  • Figure 13 GLOBAL FORECAST OF THE INFLUENZA MARKET BY PRODUCT SEGMENT, 2003-2010 ($ MILLION)
  • INDUSTRY PARTICIPANTS
  • Table 36 MAJOR INDUSTRY PARTICIPANTS BY PRODUCT SEGMENT

COMPANY PROFILES

  • ACAMBIS
  • ALPHAVAX, INC.
  • ALNYLAM PHARMACEUTICALS
  • APPLIED BIOSYSTEMS
  • AVI BIOPHARMA
  • BECTON-DICKINSON
  • BIOCRYST PHARMACEUTICALS, INC.
  • BIOTA HOLDINGS LTD.
  • CHIRON CORP.
  • ENDO PHARMACEUTICALS HOLDINGS INC.
  • FOREST LABORATORIES, INC.
  • GLAXOSMITHKLINE PLC
  • HEMISPHERX BIOPHARMA, INC.
  • INVERNESS MEDICAL-BIOSTAR, INC.
  • MEDIMMUNE VACCINES, INC.
  • OTSUKA PHARMACEUTICAL CO., LTD.
  • PATHOLOGY ASSOCIATES MEDICAL LABORATORIES (PAML)
  • QUEST DIAGNOSTICS
  • QUIDEL CORP.
  • REMEL, INC.
  • ROCHE HOLDINGS LTD.
  • SANOFI PASTEUR
  • SOLVAY PHARMACEUTICALS, INC.
  • SYSMEX CORP.
  • TEVA PHARMACEUTICALS INDUSTRIES LTD.
  • VIROMED LABORATORIES, INC.
  • ZYMETX, INC.

APPENDIX

  • Figure 14 COMPANIES MENTIONED IN THE MARKET FOR INFLUENZA TREATMENTS AND DIAGNOSTICS, BY TYPE (NUMBER OF COMPANIES)
  • Figure 14 (CONTINUED)
    • LEADING PRODUCT PROVIDERS
      • LEADING PRODUCT PROVIDERS (CONTINUED)
      • LEADING PRODUCT PROVIDERS (CONTINUED)
      • LEADING PRODUCT PROVIDERS (CONTINUED)
      • LEADING PRODUCT PROVIDERS (CONTINUED)
      • LEADING PRODUCT PROVIDERS (CONTINUED)
    • RESEARCH AND DEVELOPMENT AND AFFILIATED COMPANIES
      • RESEARCH AND DEVELOPMENT AND...(CONTINUED)
      • RESEARCH AND DEVELOPMENT AND...(CONTINUED)
      • RESEARCH AND DEVELOPMENT AND...(CONTINUED)
      • RESEARCH AND DEVELOPMENT AND...(CONTINUED)
      • RESEARCH AND DEVELOPMENT AND...(CONTINUED)
      • RESEARCH AND DEVELOPMENT AND...(CONTINUED)
      • RESEARCH AND DEVELOPMENT AND...(CONTINUED)
      • RESEARCH AND DEVELOPMENT AND...(CONTINUED)
    • MENTIONED UNIVERSITIES
      • MENTIONED UNIVERSITIES (CONTINUED)
      • MENTIONED UNIVERSITIES (CONTINUED)
    • RELEVANT ASSOCIATIONS AND ORGANIZATIONS
      • RELEVANT ASSOCIATIONS AND ... (CONTINUED)
      • RELEVANT ASSOCIATIONS AND ... (CONTINUED)
      • RELEVANT ASSOCIATIONS AND ... (CONTINUED)
      • RELEVANT ASSOCIATIONS AND ... (CONTINUED)

LIST OF TABLES

  • Summary Table:
    • GLOBAL FORECAST OF THE INFLUENZA MARKET BY PRODUCT SEGMENT, THROUGH 2010 ($ MILLION)
  • Table 1 VACCINE RECOMMENDATIONS
  • Table 2 WORLDWIDE INFLUENZA ACTIVITY
  • Table 3 VIRAL SURVEILLANCE, PERCENTAGE OF INFLUENZA VIRUS TYPE, 2004-2005 AND 2005-2006 FLU SEASONS (%)
  • Table 4 INFLUENZA RESEARCH TEAMS AND AREAS OF STUDY
  • Table 5 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP, 2003-2010 (MILLIONS)
  • Table 6 ESTIMATED WORLD POPULATION INCLUDING SOME COUNTRIES, 2003-2010 (MILLIONS)
  • Table 7 WORLDWIDE VIRAL STATISTICS, 2005
  • Table 8 UNITED STATES VIRAL STATISTICS, 2005
  • Table 9 COUNTRIES WITH U.S. EMBARGOES FOR BIRDS
  • Table 10 WHO REPORTED CASES OF AVIAN FLU IN HUMANS, MARCH 2006
  • Table 11 APPROVED WHO INFLUENZA CENTERS BY REGION
  • Table 12 CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE, 2003 TO PRESENT
  • Table 13 ALLOCATED FUNDS FOR INFLUENZA RESEARCH AND DEVELOPMENT
  • Table 14 ESTIMATED INCIDENCE OF INFLUENZA IN SEVERE OUTBREAKS BASED ON POPULATION ESTIMATES, U.S. CENSUS BUREAU INTERNATIONAL DATABASE
  • Table 15 PREDICTED IMPACT ON HEALTH SERVICES FROM THE NEXT INFLUENZA PANDEMIC IN THE TROPICS, BASED ON CDC'S FLUAID PREDICTION MODEL FOR PEAK WEEK
  • Table 16 U.S. PATENT EVALUATION FOR MAJOR TECHNOLOGY BY ISSUE DATE
  • Table 17 U.S. PATENT EVALUATION FOR MAJOR INFLUENZA MARKET COMPETITORS, BY PATENT HOLDER AND NUMBER OF PATENTS
  • Table 18 MARKETED FLU VIRUS PRODUCTS, THROUGH 2005
  • Table 19 GENERIC AVAILABILITY
  • Table 20 VACCINE AVERAGE PRICE PER UNIT DOSE, 2005-2006 INFLUENZA SEASON
  • Table 21 RESEARCH AND DEVELOPMENT EFFORTS BY STATUS
  • Table 22 GLOBAL FORECAST FOR INFLUENZA THERAPEUTIC AND VACCINE REVENUES BY MARKET, THROUGH 2010 ($ MILLIONS)
  • Table 23 GLOBAL FORECAST FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, THROUGH 2010 ($ MILLIONS)
  • Table 24 UNITS FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT, 2005-2006 SEASON (MILLION UNITS)
  • Table 25 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, 2005 (%)
  • Table 26 INFLUENZA DIAGNOSTIC TABLE
  • Table 27 MARKETED PRODUCTS, THROUGH 2005
  • Table 28 RAPID INFLUENZA TESTS AVERAGE PRICE
  • Table 29 PROVIDERS OF LABORATORY TEST SERVICES
  • Table 30 REVENUES FOR INFLUENZA DIAGNOSTICS BY MARKET, THROUGH 2010 ($ MILLIONS)
  • Table 31 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, THROUGH 2010 ($ MILLIONS)
  • Table 32 GLOBAL FORECAST OF INFLUENZA DIAGNOSTICS SERVICE REVENUES, THROUGH 2010 ($ MILLIONS)
  • Table 33 GLOBAL FORECAST OF INFLUENZA DIAGNOSTIC PRODUCT AND SERVICES MARKET REVENUES, THROUGH 2010 ($ MILLION)
  • Table 34 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENT, 2005 (%)
  • Table 35 GLOBAL FORECAST OF THE INFLUENZA MARKET BY PRODUCT SEGMENT, THROUGH 2010 ($ MILLION)
  • Table 36 MAJOR INDUSTRY PARTICIPANTS BY PRODUCT SEGMENT

LIST OF FIGURES

  • Summary Figure:
    • WORLDWIDE INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT, 2003-2010 ($ MILLIONS)
  • Figure 1 ESTIMATED WORLD POPULATION BY SELECTED AGE GROUP, 2003-2010 (MILLIONS)
  • Figure 2 ESTIMATED WORLD POPULATION BY REGION, 2003-2010 (MILLIONS)
  • Figure 3 U.S. PATENT EVALUATION FOR MAJOR INFLUENZA TECHNOLOGY PATENT HOLDERS, BY PERCENT (%)
  • Figure 4 GLOBAL FORECAST FOR INFLUENZA THERAPEUTICS AND VACCINES BY REGION, 2003-2010 ($ MILLIONS)
  • Figure 5 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, 2003-2010 ($ MILLIONS)
  • Figure 6 SHARE OF UNITS FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT, 2005-2006 SEASON (%)
  • Figure 7 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, 2005 (%)
  • Figure 8 REVENUES FOR INFLUENZA DIAGNOSTICS BY MARKET, 2003-2010 ($ MILLIONS)
  • Figure 9 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, 2003-2010 ($ MILLIONS)
  • Figure 10 REVENUES FOR INFLUENZA DIAGNOSTICS SERVICES, 2003-2010 ($ MILLIONS)
  • Figure 11 GLOBAL INFLUENZA DIAGNOSTIC PRODUCT AND SERVICES MARKET REVENUES, 2003-2010 ($ MILLION)
  • Figure 12 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENT, 2005
  • Figure 13 GLOBAL FORECAST OF THE INFLUENZA MARKET BY PRODUCT SEGMENT, 2003-2010 ($ MILLION)
  • Figure 14 COMPANIES MENTIONED IN THE MARKET FOR INFLUENZA TREATMENTS AND DIAGNOSTICS, BY TYPE (NUMBER OF COMPANIES)

The Worldwide Influenza Market

Publisher: Business Communications Co., Inc.

Format Price Order
PDF by E-mail (Single User License) US $4850.00
Hard Copy US $4850.00
PDF by E-mail (Site License) US $5950.00
PDF by E-Mail (Corporate Use License) US $8500.00
All orders are processed by "www.the-infoshop.com". www.the-infoshop.com is another Global Information web site. This transfer is entirely safe.
Copyright© 2008 GII - All Rights Reserved.